Department of Neurology, Albert Szent-Györgyi Faculty of Medicine and Clinical Centre, University of Szeged, H-6722 Szeged, Hungary.
MTA-SZTE Neuroscience Research Group, University of Szeged, H-6722 Szeged, Hungary.
Int J Mol Sci. 2022 May 5;23(9):5162. doi: 10.3390/ijms23095162.
Multiple sclerosis (MS) is the inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS) that affects approximately 2.8 million people worldwide. In the last decade, a new era was heralded in by a new phenotypic classification, a new diagnostic protocol and the first ever therapeutic guideline, making personalized medicine the aim of MS management. However, despite this great evolution, there are still many aspects of the disease that are unknown and need to be further researched. A hallmark of these research are molecular biomarkers that could help in the diagnosis, differential diagnosis, therapy and prognosis of the disease. Proteomics, a rapidly evolving discipline of molecular biology may fulfill this dire need for the discovery of molecular biomarkers. In this review, we aimed to give a comprehensive summary on the utility of proteomics in the field of MS research. We reviewed the published results of the method in case of the pathogenesis of the disease and for biomarkers of diagnosis, differential diagnosis, conversion of disease courses, disease activity, progression and immunological therapy. We found proteomics to be a highly effective emerging tool that has been providing important findings in the research of MS.
多发性硬化症（MS）是一种影响全球约 280 万人的中枢神经系统（CNS）炎症性脱髓鞘和神经退行性疾病。在过去的十年中，一种新的表型分类、一种新的诊断方案和有史以来第一个治疗指南开创了一个新时代，使个性化医学成为 MS 管理的目标。然而，尽管有了这一巨大的发展，该疾病仍有许多未知的方面需要进一步研究。这些研究的一个标志是分子生物标志物，它可以帮助疾病的诊断、鉴别诊断、治疗和预后。蛋白质组学是分子生物学中一个快速发展的学科，可能满足发现分子生物标志物的迫切需求。在这篇综述中，我们旨在全面总结蛋白质组学在 MS 研究领域的应用。我们回顾了该方法在疾病发病机制以及诊断、鉴别诊断、疾病病程转换、疾病活动、进展和免疫治疗的生物标志物方面的已发表结果。我们发现蛋白质组学是一种非常有效的新兴工具，在 MS 的研究中提供了重要的发现。
